Chlorpromazine, Hydrochloride

sc-202537

Material Safety Data Sheet

Hazard Alert Code Key:
- EXTREME
- HIGH
- MODERATE
- LOW

Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME
Chlorpromazine, Hydrochloride

STATEMENT OF HAZARDOUS NATURE

NFPA

SUPPLIER
Santa Cruz Biotechnology, Inc.
2145 Delaware Avenue
Santa Cruz, California 95060
800.457.3801 or 831.457.3800

EMERGENCY
ChemWatch
Within the US & Canada: 877-715-9305
Outside the US & Canada: +800 2436 2255
(1-800-CHEMCALL) or call +613 9573 3112

SYNONYMS

Section 2 - HAZARDS IDENTIFICATION

CHEMWATCH HAZARD RATINGS

<table>
<thead>
<tr>
<th>Hazard</th>
<th>Min</th>
<th>Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flammability</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Toxicity</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Body Contact</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Reactivity</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>
EMERGENCY OVERVIEW

RISK
Toxic if swallowed.
Very toxic by inhalation.
May cause SENSITISATION by skin contact.
Skin contact may produce health damage*.
Cumulative effects may result following exposure*.
Limited evidence of a carcinogenic effect*.
May be harmful to the foetus/embryo*.
*(limited evidence).

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED
■ Toxic effects may result from the accidental ingestion of the material; animal experiments indicate that ingestion of less than 40 gram may be fatal or may produce serious damage to the health of the individual.
■ Side-effects of chlorpromazine therapy include drowsiness, dryness of the mouth, nasal congestion, postural hypotension, lowered body temperature (occasional pyrexia), tachycardia, arrhythmias, agitation, depression, insomnia, miosis and mydriasis, convulsions, inhibition of ejaculation, photosensitivity, urticaria, skin rashes and exfoliative dermatitis. Jaundice of the obstructive type is probably allergic in its origin.
■ The use of antipsychotic drugs has been associated with a symptom complex known as Neuroleptic Malignant Syndrome (NMS). This can potentially cause death. It shows as high fever, muscle stiffness, altered mental state, and evidence of instability in the autonomic nervous system (irregular pulse or blood pressure, fast heart rate, tachycardia, sweating and heartbeat irregularities). Additional signs include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis) and acute kidney failure. Antipsychotic drugs may also produce potentially irreversible, involuntary movements (dyskinesia) especially in the elderly (women particularly). This is generally related to the duration of treatment and total cumulative dose, but can develop after low doses. Other side-effects include a disruption to the body's ability to reduce body temperature and difficulty swallowing.
■ Hypotension is more likely with phenothiazine sedatives with an aliphatic (dimethylaminopropyl) side-chain.

EYE
■ Although the material is not thought to be an irritant (as classified by EC Directives), direct contact with the eye may cause transient discomfort characterised by tearing or conjunctival redness (as with windburn). Slight abrasive damage may also result. The material may produce foreign body irritation in certain individuals.

SKIN
■ The material is not thought to be a skin irritant (as classified by EC Directives using animal models). Abrasive damage however, may result from prolonged exposures. Good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an occupational setting.
■ Skin contact with the material may damage the health of the individual; systemic effects may result following absorption.
■ People handling chlorpromazine have developed a contact dermatitis and a light-mediated skin inflammation. A purple discolouration of the skin may also occur.
■ Open cuts, abraded or irritated skin should not be exposed to this material.
■ Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.

INHALED
■ Inhalation of dusts, generated by the material, during the course of normal handling, may produce severely toxic effects; these may be fatal.
■ The material is not thought to produce respiratory irritation (as classified by EC Directives using animal models). Nevertheless inhalation of dusts, or fumes, especially for prolonged periods, may produce respiratory discomfort and occasionally, distress.
■ Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.
If prior damage to the circulatory or nervous systems has occurred or if kidney damage has been sustained, proper screenings should be conducted on individuals who may be exposed to further risk if handling and use of the material result in excessive exposures.

CHRONIC HEALTH EFFECTS
■ Skin contact with the material is more likely to cause a sensitisation reaction in some persons compared to the general population. There has been some concern that this material can cause cancer or mutations but there is not enough data to make an assessment. Substance accumulation, in the human body, may occur and may cause some concern following repeated or long-term occupational
exposure. There is some evidence from animal testing that exposure to this material may result in toxic effects to the unborn baby. Antipsychotic drugs have been shown, in animal experiments, to increase the rate of breast tumours. However, the relevance of this in humans is not known. Oral administration of phenothiazines with an aliphatic side chain, during the first three months of pregnancy, has been associated with malformations amongst offspring. Exposure to the material for prolonged periods may cause physical defects in the developing embryo (teratogenesis). Chronic constipation and faecal impaction may occur over a long period.

### Section 3 - COMPOSITION / INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>NAME</th>
<th>CAS RN</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlorpromazine, Hydrochloride</td>
<td>69-09-0</td>
<td>&gt;98</td>
</tr>
</tbody>
</table>

### Section 4 - FIRST AID MEASURES

**SWALLOWED**
- IF SWALLOWED, REFER FOR MEDICAL ATTENTION, WHERE POSSIBLE, WITHOUT DELAY.
- For advice, contact a Poisons Information Centre or a doctor.
- Urgent hospital treatment is likely to be needed.
- In the mean time, qualified first-aid personnel should treat the patient following observation and employing supportive measures as indicated by the patient's condition.
- If the services of a medical officer or medical doctor are readily available, the patient should be placed in his/her care and a copy of the MSDS should be provided. Further action will be the responsibility of the medical specialist.
- If medical attention is not available on the worksite or surroundings send the patient to a hospital together with a copy of the MSDS. Where medical attention is not immediately available or where the patient is more than 15 minutes from a hospital or unless instructed otherwise:
  - INDUCE vomiting with fingers down the back of the throat, ONLY IF CONSCIOUS. Lean patient forward or place on left side (head-down position, if possible) to maintain open airway and prevent aspiration.
  - NOTE: Wear a protective glove when inducing vomiting by mechanical means.

**EYE**
- If this product comes in contact with the eyes:
  - Immediately hold eyelids apart and flush the eye continuously with running water.
  - Ensure complete irrigation of the eye by keeping eyelids apart and away from eye and moving the eyelids by occasionally lifting the upper and lower lids.
  - Continue flushing until advised to stop by the Poisons Information Centre or a doctor, or for at least 15 minutes.
  - Transport to hospital or doctor without delay.
  - Removal of contact lenses after an eye injury should only be undertaken by skilled personnel.

**SKIN**
- If skin contact occurs:
  - Immediately remove all contaminated clothing, including footwear.
  - Flush skin and hair with running water (and soap if available).
  - Seek medical attention in event of irritation.

**INHALED**
- If fumes or combustion products are inhaled remove from contaminated area.
- Lay patient down. Keep warm and rested.
- Prostheses such as false teeth, which may block airway, should be removed, where possible, prior to initiating first aid procedures.
- Apply artificial respiration if not breathing, preferably with a demand valve resuscitator, bag-valve mask device, or pocket mask as trained. Perform CPR if necessary.
- Transport to hospital, or doctor, without delay.

**NOTES TO PHYSICIAN**
- The management of NMS (Neuroleptic Malignant syndrome) should include:
  - immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy;
  - intensive symptomatic treatment and medical monitoring and
  - treatment of any concomitant serious medical problems for which specific treatments are available.
- There is no general agreement about specific pharmacological regimes for NMS. Following recent ingestion of an overdose of phenothiazine sedatives, the stomach should be emptied by gastric lavage, and aspiration. Management should include intensive symptomatic, and supportive therapy. In particular attention should be paid to the maintenance of respiratory and renal function and to the maintenance of electrolyte balance. Phenothiazine-induced hypotension should NOT be managed with adrenalin or other sympathomimetics with beta-adrenergic agonist properties since the alpha-blocking effects of phenothiazines impair vasoconstriction and these agents may exacerbate hypotension. MARTINDALE: The Extra Pharmacopoeia, 29th Edition.
Section 5 - FIRE FIGHTING MEASURES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vapour Pressure (mmHG)</td>
<td>Negligible</td>
</tr>
<tr>
<td>Upper Explosive Limit (%)</td>
<td>Not available</td>
</tr>
<tr>
<td>Specific Gravity (water=1)</td>
<td>Not available</td>
</tr>
<tr>
<td>Lower Explosive Limit (%)</td>
<td>Not available</td>
</tr>
</tbody>
</table>

**EXTINGUISHING MEDIA**

- Water spray or fog.
- Foam.
- Dry chemical powder.
- BCF (where regulations permit).
- Carbon dioxide.

**FIRE FIGHTING**

- Alert Fire Brigade and tell them location and nature of hazard.
- Wear full body protective clothing with breathing apparatus.
- Prevent, by any means available, spillage from entering drains or water course.
- Use fire fighting procedures suitable for surrounding area.
- Do not approach containers suspected to be hot.
- Cool fire exposed containers with water spray from a protected location.
- If safe to do so, remove containers from path of fire.
- Equipment should be thoroughly decontaminated after use.

When any large container (including road and rail tankers) is involved in a fire, consider evacuation by 800 metres in all directions.

**GENERAL FIRE HAZARDS/HAZARDOUS COMBUSTIBLE PRODUCTS**

- Combustible solid which burns but propagates flame with difficulty; it is estimated that most organic dusts are combustible (circa 70%) - according to the circumstances under which the combustion process occurs, such materials may cause fires and / or dust explosions.
- Organic powders when finely divided over a range of concentrations regardless of particulate size or shape and suspended in air or some other oxidizing medium may form explosive dust-air mixtures and result in a fire or dust explosion (including secondary explosions).
- Avoid generating dust, particularly clouds of dust in a confined or unventilated space as dusts may form an explosive mixture with air, and any source of ignition, i.e. flame or spark, will cause fire or explosion. Dust clouds generated by the fine grinding of the solid are a particular hazard; accumulations of fine dust (420 micron or less) may burn rapidly and fiercely if ignited - particles exceeding this limit will generally not form flammable dust clouds.; once initiated, however, larger particles up to 1400 microns diameter will contribute to the propagation of an explosion.
- In the same way as gases and vapours, dusts in the form of a cloud are only ignitable over a range of concentrations; in principle, the concepts of lower explosive limit (LEL) and upper explosive limit (UEL) are applicable to dust clouds but only the LEL is of practical use; - this is because of the inherent difficulty of achieving homogeneous dust clouds at high temperatures (for dusts the LEL is often called the "Minimum Explosible Concentration", MEC)
- When processed with flammable liquids/vapors/mists, ignitable (hybrid) mixtures may be formed with combustible dusts. Ignitable mixtures will increase the rate of explosion pressure rise and the Minimum Ignition Energy (the minimum amount of energy required to ignite dust clouds - MIE) will be lower than the pure dust in air mixture. The Lower Explosive Limit (LEL) of the vapour/dust mixture will be lower than the individual LELs for the vapors/mists or dusts.
- A dust explosion may release of large quantities of gaseous products; this in turn creates a subsequent pressure rise of explosive force capable of damaging plant and buildings and injuring people.
- Usually the initial or primary explosion takes place in a confined space such as plant or machinery, and can be of sufficient force to damage or rupture the plant. If the shock wave from the primary explosion enters the surrounding area, it will disturb any settled dust layers, forming a second dust cloud, and often initiate a much larger secondary explosion. All large scale explosions have resulted from chain reactions of this type.
- Dry dust can be charged electrostatically by turbulence, pneumatic transport, pouring, in exhaust ducts and during transport.
- Build-up of electrostatic charge may be prevented by bonding and grounding.
- Powder handling equipment such as dust collectors, dryers and mills may require additional protection measures such as explosion venting.
- All movable parts coming in contact with this material should have a speed of less than 1-meter/sec
- A sudden release of statically charged materials from storage or process equipment, particularly at elevated temperatures and/ or pressure, may result in ignition especially in the absence of an apparent ignition source.
- One important effect of the particulate nature of powders is that the surface area and surface structure (and often moisture content) can vary widely from sample to sample, depending of how the powder was manufactured and handled; this means that it is virtually impossible to use flammability data published in the literature for dusts (in contrast to that published for gases and vapours).
- Autoignition temperatures are often quoted for dust clouds (minimum ignition temperature (MIT)) and dust layers (layer ignition temperature (LIT)). LIT generally falls as the thickness of the layer increases.

Combustion products include: carbon monoxide (CO), carbon dioxide (CO2), hydrogen chloride, phosgene, nitrogen oxides (NOx), sulfur oxides (SOx), other pyrolysis products typical of burning organic material. May emit poisonous fumes.
FIRE INCOMPATIBILITY

- Avoid contamination with oxidising agents i.e. nitrates, oxidising acids, chlorine bleaches, pool chlorine etc. as ignition may result

Section 6 - ACCIDENTAL RELEASE MEASURES

MINOR SPILLS

- Clean up waste regularly and abnormal spills immediately.
- Avoid breathing dust and contact with skin and eyes.
- Wear protective clothing, gloves, safety glasses and dust respirator.
- Use dry clean up procedures and avoid generating dust.
- Vacuum up or sweep up. NOTE: Vacuum cleaner must be fitted with an exhaust micro filter (HEPA type) (consider explosion-proof machines designed to be grounded during storage and use).
- Dampen with water to prevent dusting before sweeping.
- Place in suitable containers for disposal.

MAJOR SPILLS

- Clear area of personnel and move upwind.
- Alert Fire Brigade and tell them location and nature of hazard.
- Wear full body protective clothing with breathing apparatus.
- Prevent, by any means available, spillage from entering drains or water course.
- Stop leak if safe to do so.
- Contain spill with sand, earth or vermiculite.
- Collect recoverable product into labelled containers for recycling.
- Neutralise/decontaminate residue (see Section 13 for specific agent).
- Collect solid residues and seal in labelled drums for disposal.
- Wash area and prevent runoff into drains.
- After clean up operations, decontaminate and launder all protective clothing and equipment before storing and re-using.
- If contamination of drains or waterways occurs, advise emergency services.

Section 7 - HANDLING AND STORAGE

PROCEDURE FOR HANDLING

- Avoid all personal contact, including inhalation.
- Wear protective clothing when risk of exposure occurs.
- Use in a well-ventilated area.
- Prevent concentration in hollows and sumps.
- DO NOT enter confined spaces until atmosphere has been checked.
- DO NOT allow material to contact humans, exposed food or food utensils.
- Avoid contact with incompatible materials.
- When handling, DO NOT eat, drink or smoke.
- Keep containers securely sealed when not in use.
- Avoid physical damage to containers.
- Always wash hands with soap and water after handling.
- Work clothes should be laundered separately. Launder contaminated clothing before re-use.
- Use good occupational work practice.
- Observe manufacturer’s storing and handling recommendations.
- Atmosphere should be regularly checked against established exposure standards to ensure safe working conditions are maintained.
- Organic powders when finely divided over a range of concentrations regardless of particulate size or shape and suspended in air or some other oxidizing medium may form explosive dust-air mixtures and result in a fire or dust explosion (including secondary explosions)
- Minimise airborne dust and eliminate all ignition sources. Keep away from heat, hot surfaces, sparks, and flame.
- Establish good housekeeping practices.
- Remove dust accumulations on a regular basis by vacuuming or gentle sweeping to avoid creating dust clouds.
- Use continuous suction at points of dust generation to capture and minimise the accumulation of dusts. Particular attention should be given to overhead and hidden horizontal surfaces to minimise the probability of a “secondary” explosion. According to NFPA Standard 654, dust layers 1/32 in.(0.8 mm) thick can be sufficient to warrant immediate cleaning of the area.
- Do not use air hoses for cleaning.
- Minimise dry sweeping to avoid generation of dust clouds. Vacuum dust-accumulating surfaces and remove to a chemical disposal area. Vacuums with explosion-proof motors should be used.
- Control sources of static electricity. Dusts or their packages may accumulate static charges, and static discharge can be a source of ignition.
- Solids handling systems must be designed in accordance with applicable standards (e.g. NFPA including 654 and 77) and other national guidance.
- Do not empty directly into flammable solvents or in the presence of flammable vapors.
- The operator, the packaging container and all equipment must be grounded with electrical bonding and grounding systems. Plastic bags and plastics cannot be grounded, and antistatic bags do not completely protect against development of static charges. Empty containers may contain residual dust which has the potential to accumulate following settling. Such dusts may explode in the presence of an appropriate ignition source.
- Do NOT cut, drill, grind or weld such containers.
- In addition ensure such activity is not performed near full, partially empty or empty containers without appropriate workplace safety authorisation or permit.

RECOMMENDED STORAGE METHODS
- Glass container is suitable for laboratory quantities
- Lined metal can, lined metal pail/ can.
- Plastic pail.
- Polyliner drum.
- Packing as recommended by manufacturer.
- Check all containers are clearly labelled and free from leaks.

For low viscosity materials
- Drums and jerricans must be of the non-removable head type.
- Where a can is to be used as an inner package, the can must have a screwed enclosure.

For materials with a viscosity of at least 2680 cSt. (23 deg. C) and solids (between 15 C deg. and 40 deg C.):
- Removable head packaging;
- Cans with friction closures and
- low pressure tubes and cartridges may be used.

Where combination packages are used, and the inner packages are of glass, there must be sufficient inert cushioning material in contact with inner and outer packages *
- In addition, where inner packagings are glass and contain liquids of packing group I and II there must be sufficient inert absorbent to absorb any spillage *
- * unless the outer packaging is a close fitting moulded plastic box and the substances are not incompatible with the plastic.

STORAGE REQUIREMENTS
- Store in original containers.
- Keep containers securely sealed.
- Store in a cool, dry, well-ventilated area.
- Store away from incompatible materials and foodstuff containers.
- Protect containers against physical damage and check regularly for leaks.
- Observe manufacturer’s storing and handling recommendations.

Section 8 - EXPOSURE CONTROLS / PERSONAL PROTECTION

EXPOSURE CONTROLS
The following materials had no OELs on our records
- chlorpromazine hydrochloride: CAS:69-09-0

PERSONAL PROTECTION

RESPIRATOR

EYE
For laboratory, larger scale or bulk handling or where regular exposure in an occupational setting occurs:
- Chemical goggles
- Face shield. Full face shield may be required for supplementary but never for primary protection of eyes
- Contact lenses may pose a special hazard; soft contact lenses may absorb and concentrate irritants. A written policy document, describing the wearing of lens or restrictions on use, should be created for each workplace or task. This should include a review of lens absorption and adsorption for the class of chemicals in use and an account of injury experience. Medical and first-aid personnel should be trained in their removal and suitable equipment should be readily available. In the event of chemical exposure, begin eye
irrigation immediately and remove contact lens as soon as practicable. Lens should be removed at the first signs of eye redness or irritation - lens should be removed in a clean environment only after workers have washed hands thoroughly. [CDC NIOSH Current Intelligence Bulletin 59], [AS/NZS 1336 or national equivalent]

HANDS/FEET
NOTE:
- The material may produce skin sensitisation in predisposed individuals. Care must be taken, when removing gloves and other protective equipment, to avoid all possible skin contact.
- Contaminated leather items, such as shoes, belts and watch-bands should be removed and destroyed.

Suitability and durability of glove type is dependent on usage. Important factors in the selection of gloves include:
- frequency and duration of contact,
- chemical resistance of glove material,
- glove thickness and dexterity

Select gloves tested to a relevant standard (e.g. Europe EN 374, US F739, AS/NZS 2161.1 or national equivalent).
- When prolonged or frequently repeated contact may occur, a glove with a protection class of 5 or higher (breakthrough time greater than 240 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.
- When only brief contact is expected, a glove with a protection class of 3 or higher (breakthrough time greater than 60 minutes according to EN 374, AS/NZS 2161.10.1 or national equivalent) is recommended.
- Contaminated gloves should be replaced.

Gloves must only be worn on clean hands. After using gloves, hands should be washed and dried thoroughly. Application of a non-perfumed moisturiser is recommended.
- Rubber gloves (nitrile or low-protein, powder-free latex, latex/ nitrile). Employees allergic to latex gloves should use nitrile gloves in preference.
- Double gloving should be considered.
- PVC gloves.
- Change gloves frequently and when contaminated, punctured or torn.
- Wash hands immediately after removing gloves.
- Protective shoe covers. [AS/NZS 2210]
- Head covering.

OTHER
- For quantities up to 500 grams a laboratory coat may be suitable.
- For quantities up to 1 kilogram a disposable laboratory coat or coverall of low permeability is recommended. Coveralls should be buttoned at collar and cuffs.
- For quantities over 1 kilogram and manufacturing operations, wear disposable coverall of low permeability and disposable shoe covers.
- For manufacturing operations, air-supplied full body suits may be required for the provision of advanced respiratory protection.
- Eye wash unit.
- Ensure there is ready access to an emergency shower.
- For Emergencies: Vinyl suit

ENGINEERING CONTROLS
- For potent pharmacological agents:
- Powders
  - To prevent contamination and overexposure, no open handling of powder should be allowed.
  - Powder handling operations are to be done in a powders weighing hood, a glove box, or other equivalent ventilated containment system.
  - In situations where these ventilated containment hoods have not been installed, a non-ventilated enclosed containment hood should be used.
  - Pending changes resulting from additional air monitoring data, up to 300 mg can be handled outside of an enclosure provided that no grinding, crushing or other dust-generating process occurs.
  - An air-purifying respirator should be worn by all personnel in the immediate area in cases where non-ventilated containment is used, where significant amounts of material (e.g., more than 2 grams) are used, or where the material may become airborne (as through grinding, etc.).
  - Powder should be put into solution or a closed or covered container after handling.
  - If using a ventilated enclosure that has not been validated, wear a half-mask respirator equipped with HEPA cartridges until the enclosure is validated for use.

Solutions Handling:
- Solutions can be handled outside a containment system or without local exhaust ventilation during procedures with no potential for aerosolisation. If the procedures have a potential for aerosolisation, an air-purifying respirator is to be worn by all personnel in the immediate area.
- Solutions used for procedures where aerosolisation may occur (e.g., vortexing, pumping) are to be handled within a containment system or with local exhaust ventilation.
- In situations where this is not feasible (may include animal dosing), an air-purifying respirator is to be worn by all personnel in the immediate area. If using a ventilated enclosure that has not been validated, wear a half-mask respirator equipped with HEPA cartridges until the enclosure is validated for use.
- Ensure gloves are protective against solvents in use.

Unless written procedures, specific to the workplace are available, the following is intended as a guide:
For laboratory-scale handling of substances assessed to be toxic by inhalation. Quantities of up to 25 grams may be handled in Class II biological safety cabinets*; quantities of 25 grams to 1 kilogram may be handled in Class II biological safety cabinets or equivalent containment systems; quantities exceeding 1 kg may be handled either using specific containment, a hood or Class II biological safety cabinet*.

HEPA terminated local exhaust ventilation should be considered at point of generation of dust, fumes or vapours.

The need for respiratory protection should also be assessed where incidental or accidental exposure is anticipated. Dependent on levels of contamination, PAPR, full face air purifying devices with P2 or P3 filters or air supplied respirators should be evaluated. When handling, quantities of up to 25 grams, an approved respirator with HEPA filters or cartridges should be considered; quantities of 25 grams to 1 kilogram, a half-face negative pressure, full negative pressure, or powered helmet-type air purifying respirator should be considered. Quantities in excess of 1 kilogram, a full face negative pressure, helmet-type air purifying, or supplied air respirator should be considered.

Written procedures, specific to a particular work-place, may replace these recommendations

* For Class II Biological Safety Cabinets, Types B2 or B3 should be considered. Where only Class I, open fronted Cabinets are available, glove panels may be added, Laminar flow cabinets do not provide sufficient protection when handling these materials unless especially designed to do so.

Pilot Plant and Production

- Wear appropriate gloves; lab coat, nylon coveralls or disposable Tyvek suit; safety glasses, safety shoes, and disposable booties.
- Use good manufacturing practices (i.e., cGMPs).
- Protective garment (coveralls, Tyvek, lab coat) is not to be worn outside the work area.
- Clean/dirty/decontamination areas are to be established.
- Negative/positive air pressure relationships and buffer zones required (i.e., ante-room/degowning room/airlock).
- Area access is to be restricted.
- High-energy operations such as milling, particle sizing, spraying or fluidising should be done within an approved emission control or containment system.
- Develop cleaning procedures and techniques that limit potential exposure

---

**PHYSICAL AND CHEMICAL PROPERTIES**

**PHYSICAL PROPERTIES**

- Solid.
- Mixes with water.

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>State</td>
<td>Divided solid</td>
</tr>
<tr>
<td>Molecular Weight</td>
<td>355.3</td>
</tr>
<tr>
<td>Melting Range (°F)</td>
<td>381-385</td>
</tr>
<tr>
<td>Boiling Range (°F)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flash Point (°F)</td>
<td>Not available</td>
</tr>
<tr>
<td>Decomposition Temp (°F)</td>
<td>Not available</td>
</tr>
<tr>
<td>Autoignition Temp (°F)</td>
<td>Not available</td>
</tr>
<tr>
<td>Upper Explosive Limit (%)</td>
<td>Not available</td>
</tr>
<tr>
<td>Lower Explosive Limit (%)</td>
<td>Not available</td>
</tr>
<tr>
<td>Volatile Component (% vol)</td>
<td>Negligible</td>
</tr>
<tr>
<td>Viscosity</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Solubility in water (g/L)</td>
<td>Miscible</td>
</tr>
<tr>
<td>pH (1% solution)</td>
<td>4-5 (10%)</td>
</tr>
<tr>
<td>pH (as supplied)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Vapour Pressure (mmHG)</td>
<td>Negligible</td>
</tr>
<tr>
<td>Specific Gravity (water=1)</td>
<td>Not available</td>
</tr>
<tr>
<td>Relative Vapour Density (air=1)</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Evaporation Rate</td>
<td>Not Applicable</td>
</tr>
</tbody>
</table>

**APPEARANCE**

Crystalline powder with very bitter taste; mixes with water (1:0.4), in alcohol (1:1.3), chloroform (1:1). Decomposes on exposure to air and light.

---

**CONDITIONS CONTRIBUTING TO INSTABILITY**

- Presence of incompatible materials.
- Product is considered stable.
- Hazardous polymerisation will not occur.

**STORAGE INCOMPATIBILITY**

- Avoid reaction with oxidising agents

For incompatible materials - refer to Section 7 - Handling and Storage.
chlorpromazine hydrochloride

TOXICITY AND IRRITATION
CHLORPROMAZINE HYDROCHLORIDE:
■ unless otherwise specified data extracted from RTECS - Register of Toxic Effects of Chemical Substances.

<table>
<thead>
<tr>
<th>TOXICITY</th>
<th>IRRITATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral (rat) LD50: 145 mg/kg</td>
<td>Nil Reported</td>
</tr>
<tr>
<td>Inhalation (rat) LC50: 40 mg/m³/2h</td>
<td></td>
</tr>
<tr>
<td>Intraperitoneal (rat) LD50: 62 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Intravenous (rat) LD50: 25 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Oral (mouse) LD50: 135 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Inhalation (mouse) LC50: 40 mg/m³/2h</td>
<td></td>
</tr>
<tr>
<td>Intraperitoneal (mouse) LD50: 92.2 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Subcutaneous (mouse) LD50: 420 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Intravenous (mouse) LD50: 20 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Intravenous (rabbit) LD50: 5 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Intraperitoneal (g.pig) LD50: 109 mg/kg</td>
<td></td>
</tr>
<tr>
<td>Subcutaneous (g.pig) LD50: 420 mg/kg</td>
<td></td>
</tr>
</tbody>
</table>

■ Contact allergies quickly manifest themselves as contact eczema, more rarely as urticaria or Quincke’s oedema. The pathogenesis of contact eczema involves a cell-mediated (T lymphocytes) immune reaction of the delayed type. Other allergic skin reactions, e.g. contact urticaria, involve antibody-mediated immune reactions. The significance of the contact allergen is not simply determined by its sensitisation potential: the distribution of the substance and the opportunities for contact with it are equally important. A weakly sensitising substance which is widely distributed can be a more important allergen than one with stronger sensitising potential with which few individuals come into contact. From a clinical point of view, substances are noteworthy if they produce an allergic test reaction in more than 1% of the persons tested.

The main side effects of chlorpromazine are due to its anticholinergic properties; These include sedation, slurred speech, dry mouth, constipation, urinary retention and possible lowering of seizure threshold. Appetite may be increased with resultant weight gain, Glucose tolerance may be impaired, resulting in increased risk of sunburn.

A more chronic side-effect is tardive dyskinesia, which may be irreversible in some patients. Neuroleptic malignant syndrome is a rare though potentially fatal outcome of any antipsychotic use - about one in two thousand (0.05%) patients taking chlorpromazine may develop it.

Other reported side effects are rare, though severe; these include a reduction in the number of white blood cells - referred to as leucopenia - or, in extreme cases, even agranulocytosis, which may occur in 0.01% of patients and lead to death via uncontrollable infections and/or sepsis. Chlorpromazine is also known to accumulate in the eye - in the posterior corneal stroma, lens, and uveal tract. Because it is a phototoxic compound, the potential exists for it to cause cellular damage after light exposure. Research confirms a significant risk of blindness from continued use of chlorpromazine, as well as other ophthalmological defects such as color blindness and benign pigmentation of the cornea.

Chlorpromazine is the neuroleptic drug with the highest rates (0.5% to 1%) of liver toxicity of the cholestatic type. The sedation effect combined with indifference to physical stimuli, anecdotally known as the "thorazine shuffle," has long been associated with the drug. The image of psychiatric patients staggering mute around a padded cell has earned those particular side effects a place in mainstream pop culture. However, heavy sedation is usually due to excessive doses of Chlorpromazine aimed at pacifying difficult patients in institutional settings. The dose required to treat psychotic symptoms is smaller and therefore less sedative than is commonly depicted.

In some rare cases psychosis or death can result as a result of the paradoxical lowering of blood pressure, or death due to cardiac arrest

Chlorpromazine works on a variety of receptors in the central nervous system; these include anticholinergic, antidopaminergic and antihistamine effects as well as some antagonism of adrenergic receptors Chlorpromazine, along with many of the older antipsychotics which have minimal effect on the serotonergic pathways, is considered a typical antipsychotic.

Exposure to the material for prolonged periods may cause physical defects in the developing embryo (teratogenesis).

Somnia, excitement, human anorexia, muscle weakness, rigidity, irritability, alteration of classic conditioning, pulse rate increase, respiratory stimulation, gastrointestinal changes, sweating, paternal effects, maternal effects, effects on fertility, extra-embryonic structures, foetotoxicity, foetal lethality, specific developmental effects (central nervous system, eye, ear, craniofacial, musculoskeletal, gastrointestinal, urogenital), effects on newborn recorded.

CARCINOGEN
chlorpromazine hydrochloride
US - Maine Chemicals of High Concern List Carcinogen
This material and its container must be disposed of as hazardous waste.

### Ecotoxicity

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Persistence: Water/Soil</th>
<th>Persistence: Air</th>
<th>Bioaccumulation</th>
<th>Mobility</th>
</tr>
</thead>
<tbody>
<tr>
<td>chlorpromazine hydrochloride</td>
<td>HIGH</td>
<td>No Data Available</td>
<td>LOW</td>
<td>LOW</td>
</tr>
</tbody>
</table>

### GESAMP/EHS COMPOSITE LIST - GESAMP Hazard Profiles

<table>
<thead>
<tr>
<th>Name / EHS</th>
<th>TRN</th>
<th>A1a</th>
<th>A1b</th>
<th>A1</th>
<th>A2</th>
<th>B1</th>
<th>B2</th>
<th>C1</th>
<th>C2</th>
<th>C3</th>
<th>D1</th>
<th>D2</th>
<th>D3</th>
<th>E1</th>
<th>E2</th>
<th>E3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cas No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RTECS No</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poly(2+ cyclic aromatics / CAS:69-09-0)</td>
<td>224</td>
<td>574</td>
<td>4</td>
<td>NR</td>
<td>(4)</td>
<td>NI</td>
<td>(1)</td>
<td>(1)</td>
<td>(2)</td>
<td>(1)</td>
<td>CM</td>
<td>S</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Legend: EHS=EHS Number (EHS=GESAMP Working Group on the Evaluation of the Hazards of Harmful Substances Carried by Ships) NRT=Net Register Tonnage, A1a=Bioaccumulation log Pow, A1b=Bioaccumulation BCF, A1=Bioaccumulation, A2=Biodegradation, B1=Acute aquatic toxicity LC50/EC50 (mg/l), B2=Chronic aquatic toxicity NOEC (mg/l), C1=Acute mammalian oral toxicity LD50 (mg/kg), C2=Acute mammalian dermal toxicity LD50 (mg/kg), C3=Acute mammalian inhalation toxicity LC50 (mg/kg), D1=Skin irritation & corrosion, D2=Eye irritation & corrosion, D3=Long-term health effects, E1=Tainting, E2=Physical effects on wildlife & benthic habitats, E3=Interference with coastal amenities, For column A2: R=Readily biodegradable, NR=Not readily biodegradable. For column D3: C=Carcinogen, M=Mutagenic, R=Reprotoxic, S=Sensitising, A=Aspiration hazard, T=Target organ systemic toxicity, L=Lung injury, N=Neurotoxic, I=Immunotoxic. For column E1: NT=Not tainting (tested), T=Tainting test positive. For column E2: Fp=Persistent floater, F=Floater, S=Sinking substances. The numerical scales start from 0 (no hazard), while higher numbers reflect increasing hazard. (GESAMP/EHS Composite List of Hazard Profiles - Hazard evaluation of substances transported by ships)

### Disposal Considerations

All waste must be handled in accordance with local, state and federal regulations.

- Containers may still present a chemical hazard/danger when empty.
- Return to supplier for reuse/recycling if possible.

Otherwise:

- If container cannot be cleaned sufficiently well to ensure that residuals do not remain or if the container cannot be used to store the same product, then puncture containers, to prevent re-use, and bury at an authorised landfill.
- Where possible retain label warnings and MSDS and observe all notices pertaining to the product.

Legislation addressing waste disposal requirements may differ by country, state and/or territory. Each user must refer to laws operating in their area. In some areas, certain wastes must be tracked. A Hierarchy of Controls seems to be common - the user should investigate:

- Reduction
- Reuse
- Recycling
- Disposal (if all else fails)

This material may be recycled if unused, or if it has not been contaminated so as to make it unsuitable for its intended use. Shelf life considerations should also be applied in making decisions of this type. Note that properties of a material may change in use, and recycling or reuse may not always be appropriate. In most instances the supplier of the material should be consulted.

- DO NOT allow wash water from cleaning or process equipment to enter drains.
- It may be necessary to collect all wash water for treatment before disposal.
- In all cases disposal to sewer may be subject to local laws and regulations and these should be considered first.
- Where in doubt contact the responsible authority.
- Recycle wherever possible.
- Consult manufacturer for recycling options or consult local or regional waste management authority for disposal if no suitable treatment or disposal facility can be identified.
- Dispose of by: burial in a land-fill specifically licenced to accept chemical and/or pharmaceutical wastes or Incineration in a licenced apparatus (after admixture with suitable combustible material)
- Decontaminate empty containers. Observe all label safeguards until containers are cleaned and destroyed.
### Section 14 - TRANSPORTATION INFORMATION

<table>
<thead>
<tr>
<th>DOT:</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symbols:</strong></td>
<td>None</td>
<td></td>
</tr>
<tr>
<td><strong>Identification Numbers:</strong></td>
<td>UN3249</td>
<td>PG:</td>
</tr>
<tr>
<td><strong>Label Codes:</strong></td>
<td>6.1</td>
<td>Special provisions: T1, TP33</td>
</tr>
<tr>
<td><strong>Packaging: Exceptions:</strong></td>
<td>153</td>
<td>Packaging: Non-bulk: 213</td>
</tr>
<tr>
<td><strong>Packaging: Exceptions:</strong></td>
<td>153</td>
<td>Quantity limitations: Passenger aircraft/rail: 5 kg</td>
</tr>
<tr>
<td><strong>Quantity Limitations: Cargo aircraft only:</strong></td>
<td>5 kg</td>
<td>Vessel stowage: Location: C</td>
</tr>
<tr>
<td><strong>Vessel stowage: Other:</strong></td>
<td>40</td>
<td></td>
</tr>
</tbody>
</table>

Hazardous materials descriptions and proper shipping names:
Medicine, solid, toxic, n.o.s.

**Air Transport IATA:**

<table>
<thead>
<tr>
<th>ICAO/IATA Class:</th>
<th>6.1</th>
<th>ICAO/IATA Subrisk: None</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>UN/ID Number:</strong></td>
<td>3249</td>
<td>Packing Group: III</td>
</tr>
<tr>
<td><strong>Special provisions:</strong></td>
<td>A3</td>
<td></td>
</tr>
</tbody>
</table>

**Cargo Only**

<table>
<thead>
<tr>
<th><strong>Packing Instructions:</strong></th>
<th>677</th>
<th>Maximum Qty/Pack: 200 kg</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Passenger and Cargo</strong></td>
<td></td>
<td>Passenger and Cargo</td>
</tr>
<tr>
<td><strong>Packing Instructions:</strong></td>
<td>670</td>
<td>Maximum Qty/Pack: 100 kg</td>
</tr>
<tr>
<td><strong>Passenger and Cargo</strong></td>
<td></td>
<td>Passenger and Cargo</td>
</tr>
<tr>
<td><strong>Limited Quantity</strong></td>
<td></td>
<td>Limited Quantity</td>
</tr>
<tr>
<td><strong>Packing Instructions:</strong></td>
<td>Y645</td>
<td>Maximum Qty/Pack: 5 kg</td>
</tr>
</tbody>
</table>

Shipping name: MEDICINE, SOLID, TOXIC, N.O.S.(contains chlorpromazine hydrochloride)

**Maritime Transport IMDG:**

<table>
<thead>
<tr>
<th>IMDG Class:</th>
<th>6.1</th>
<th>IMDG Subrisk: None</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>UN Number:</strong></td>
<td>3249</td>
<td>Packing Group: III</td>
</tr>
<tr>
<td><strong>EMS Number:</strong></td>
<td>F-A,S-A</td>
<td>Special provisions: 221 223</td>
</tr>
<tr>
<td><strong>Limited Quantities:</strong></td>
<td>5 kg</td>
<td></td>
</tr>
</tbody>
</table>

Shipping name: MEDICINE, SOLID, TOXIC, N.O.S.(contains chlorpromazine hydrochloride)

### Section 15 - REGULATORY INFORMATION

chlorpromazine hydrochloride (CAS: 69-09-0) is found on the following regulatory lists:

*Canada CEPA Environmental Registry Substance Lists - List of substances on the DSL that are Inherently Toxic to the Environment (English)*,
*Canada CEPA Environmental Registry Substance Lists - List of substances on the DSL that are Inherently Toxic to the Environment (French)*,
*Canada Domestic Substances List (DSL)*,
*Canada List of Prohibited and Restricted Cosmetic Ingredients (The Cosmetic Ingredient "Hotlist")*,
*Canada Substances in Products Regulated Under the Food and Drugs Act (F&DA) That Were In Commerce between January 1, 1987 and September 13, 2001 (English)*,
*GESAMP/EHS Composite List - GESAMP Hazard Profiles*,
*IMO Provisional Categorization of Liquid Substances - List 2: Pollutant only mixtures containing at least 99% by weight of components already assessed by IMO*,
*IMO Provisional Categorization of Liquid Substances - List 3: (Trade-named) mixtures containing at least 99% by weight of components already assessed by IMO, presenting safety hazards*,
*US - California Occupational Health and Safety Enforcement*.
LIMITED EVIDENCE

- Skin contact may produce health damage*.
- Cumulative effects may result following exposure*.
- Limited evidence of a carcinogenic effect*.
- May be harmful to the foetus/embryo*.

* (limited evidence).

Denmark Advisory list for selfclassification of dangerous substances

<table>
<thead>
<tr>
<th>Substance</th>
<th>CAS</th>
<th>Suggested codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>chlorpromazine hydrochloride</td>
<td>69-09-0</td>
<td>Mut3; R68 T;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R25; N; R50/53</td>
</tr>
</tbody>
</table>

- Classification of the preparation and its individual components has drawn on official and authoritative sources as well as independent review by the Chemwatch Classification committee using available literature references.

A list of reference resources used to assist the committee may be found at: www.chemwatch.net/references.

- The (M)SDS is a Hazard Communication tool and should be used to assist in the Risk Assessment. Many factors determine whether the reported Hazards are Risks in the workplace or other settings. Risks may be determined by reference to Exposures Scenarios. Scale of use, frequency of use and current or available engineering controls must be considered.

- For detailed advice on Personal Protective Equipment, refer to the following U.S. Regulations and Standards:
  - OSHA Standards - 29 CFR:
    - 1910.132 - Personal Protective Equipment - General requirements
    - 1910.133 - Eye and face protection
    - 1910.134 - Respiratory Protection
    - 1910.136 - Occupational foot protection
    - 1910.138 - Hand Protection
    - Eye and face protection - ANSI Z87.1
    - Foot protection - ANSI Z41
  - Respirators must be NIOSH approved.

This document is copyright. Apart from any fair dealing for the purposes of private study, research, review or criticism, as permitted under the Copyright Act, no part may be reproduced by any process without written permission from CHEMWATCH. TEL (+61 3) 9572 4700.

www.Chemwatch.net

Issue Date: Apr-12-2009
Print Date: Feb-28-2012